Seeking Alpha

Seeking Alpha Portfolio App for iPad

2,714 people get REGN articles and Market Currents by email alert.

Get email alerts on REGN »

REGN

Regeneron Pharmaceuticals, Inc.

6/19/2013, 11:02 PM ET

Quote & Headlines Market Currents StockTalk

All
| Earnings
| Dividends
| M&A
| On the move

Thursday, June 6, 3:04 PM Regeneron Pharmaceuticals (REGN +7.6%) takes another leg higher, breaking out on the back of news posted earlier of positive top-line results for Eylea. Comment! [Healthcare, On the Move]
Thursday, June 6, 6:12 AM Regeneron (REGN) and Bayer's (BAYZF.PK) Eylea treatment helped improve the clearness of patients' vision in those with myopic choroidal neovascularization (mCNV) in a Phase III trial. mCNV is a disease where abnormal blood vessels grow into the retina in people who are severely short-sighted. Bayer now expects to submit the first application for regulatory approval of Eylea for mCNV in Asia in H2. (PR) Comment! [Healthcare]
Thursday, May 16, 1:49 PM Biotech names are weak today on the back of several ASCO data presentation releases: REGN -2.3%, ALXN -4.2%, VRTX -2.3%, CELG -4.5%, ARRY -2.2%, AMGN -1.4%. 1 Comment [Healthcare, On the Move]
Wednesday, May 15, 3:10 PM Regeneron Pharmaceuticals (REGN -3.2%) and Sanofi (SNY -0.7%) have enrolled the first patients for trials of sarilumab, an injection to treat moderate-to-severe rheumatoid arthritis patients who are inadequate responders to either methotrexate or tumor necrosis factor alpha inhibitor therapy. Comment! [Healthcare, Global & FX]
Monday, May 6, 3:27 PM Appearing a bit late to the party, Jefferies raises its price target on Regeneron Pharmaceuticals (REGN -1.3%) to $247 from $179 citing the company's top line, EYLEA sales-driven earnings beat. Jefferies is responding to REGN's hike of FY13 EYLEA sales estimates — the company pointed to a strong ex-U.S. rollout. Q1 sales of the macular degeneration injection were $314M compared to $124M in Q1 2012. 1 Comment [Healthcare]
Friday, May 3, 7:35 AM More on Regeneron's (REGN) Q1 : The company exhibits "sustained revenue and earnings growth" helped by strong EYLEA sales growth in the U.S. (FY13 U.S. sales estimates for the macular degeneration injection hiked to $1.25-1.325B) and a healthy roll out of the drug outside the country by partner Bayer Healthcare. Late stage pipeline makes progress. Shares +5% premarket. ( PR ) Comment! [Healthcare, Earnings, On the Move]
Friday, May 3, 7:04 AM Regeneron Pharmaceuticals (REGN): Q1 EPS of $1.78 beats by $0.37. Revenue of $440M beats by $15.74M. (PR) Comment! [Earnings, Breaking News, Healthcare]
Friday, May 3, 12:05 AM Notable earnings before Friday’s open: ADP, AXL, BBEP, BPL, CBOE, DUK, FBN, GBDC, GTXI, HST, LNT, MCO, NGLS, NRF, NVE, NWL, PNW, POM, PPC, REGN, SE, SEP, SMP, UPL, WCG, XLS, YRCW Comment! [Earnings]
Thursday, May 2, 5:30 PM Notable earnings before Friday’s open: ADP, AXL, BBEP, BPL, CBOE, DUK, FBN, GBDC, GTXI, HST, LNT, MCO, NGLS, NRF, NVE, NWL, PNW, POM, PPC, REGN, SE, SEP, SMP, UPL, WCG, XLS, YRCW Comment! [Earnings]
Wednesday, May 1, 12:50 PM Midday top 10 gainers: IQNT +60%. BCOV +31%. CNIT +28%. MNOV +21%. MSPD +19%. SONS +15%. TRLA +15%. RATE +15%. REGN +14%. SGI +14%.
Midday top 10 losers: ACCL -21%. RBC -20%. ESBF -17%. LEDS -16%. KFRC -15%. AGN -14%. CRAY -13%. ASTX -13%. XXIA -13%. UTI -12%. Comment! [On the Move]
Wednesday, May 1, 11:23 AM Allergan (AGN -9.4%) dives as management - on today's earnings call - has less than great progress to report on a couple of drugs in development. Regeneron (REGN +12.4%) spikes higher. 1 Comment [Healthcare, Breaking News, On the Move]
Wednesday, May 1, 10:36 AM Goldman raises its price target on Regeneron Pharmaceuticals (REGN +3%) to $240 from $230 after a survey of 41 U.S.-based cardiologists/lipidologists shows awareness of anti-PCSK9 drugs is widespread and "physicians project to use this class of drugs in 25-50% of their patients one year after approval." Putting it all together, Goldman hikes its peak sales estimates for REGN727 (developed with Sanofi SNY) to $3.5B from $3B and says it expects the company to report Phase III data in Q3. (Previoulsly: GS reiterates Buy on REGN) Comment! [Healthcare, On the Move]
Wednesday, April 24, 5:46 PM S&P announces some changes to its index lineup today: Regeneron Pharmaceuticals (REGN) will join the S&P 500, replacing MetroPCS (PCS) which is being acquired by T-Mobile USA. S&P SmallCap 600 constituent Eagle Materials (EXP) will replace REGN in the S&P MidCap 400, and Francesca's Holdings (FRAN) will replace Eagle Materials in the S&P SmallCap 600 after the close of trading on Tuesday, April 30. 1 Comment [Healthcare, Tech, Commodities, Consumer]
Tuesday, April 9, 11:33 AM Regeneron (REGN +1.7%) gets a lift today as Goldman reiterates its Buy recommendation and raises its price target on the shares to $215 from $196 citing relative YTD underperformance versus the Nasdaq Biotech index and a strong Eylea launch. Comment! [Healthcare, On the Move]
Thursday, February 14, 8:23 AM More on Regeneron Pharma (REGN +1.6%) Q4: swings to net profit of $470M from a net loss of $53.4M as sales more than triple, with its Eylea eyecare product bringing in $276M. Earnings also include $127M in collaboration revenues and a non-cash tax benefit of $336M. Forecasts 2013 Eyelea sales of $1.2-1.3B in the U.S. Partner Bayer has started to launch the product overseas. (PR) 1 Comment [Earnings, Healthcare]
Thursday, February 14, 6:32 AM Regeneron Pharma (REGN): Q4 EPS of $1.47 beats by $0.23. Revenue of $415M beats by $22.36M. (PR) 1 Comment [Earnings, Breaking News, Healthcare]